References
- Guerra L, Dellambra E, Brescia S, Raskovic D. Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab. 2010;11:451–467.
- Jimbow K. Vitiligo. Therapeutic advances. Dermatol Clin. 1998;16:399–407.
- Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, et al. Vitiligo: concise evidence based guidelines on diagnosis and management. Postgrad Med J. 2010;86:466–471.
- El Mofty M, Mostafa W, Esmat S, Youssef R, Azzam O, Hunter N, et al. Narrow band Ultraviolet B 311 nm in the treatment of vitiligo: two right-left comparison studies. Photodermatol Photoimmunol Photomed. 2006;22:6–11.
- Imukawa G, Miyagishi M, Yada Y. Endothelin-1 as a new melanogen: coordinated expression of its gene and the tyrosinase gene in UVB-exposed human epidermis. J Invest Dermatol. 1995;105:32–37.
- Wu CS, Yu CL, Lan CC, Yu HS. Narrow-band ultraviolet-B stimulates proliferation and migration of cultured melanocytes. Exp Dermatol. 2004;13:755–763.
- Bagot M, Charue D, Lescs MC, Pamphıle R, Revuz J. Immunosuppressive of 1.25-Dihiroxyvitamin D3 and its analogue on epidermal cells. Br J Dermatol. 1994;130:424–431.
- Parsad D, Saini R, Verma N. Combination of puvasol and vitiligo calcipotriol in vitiligo. Dermatology. 1998;197:167–170.
- Bikle DD. Vitamin D: a calciotropic hormone regulating calcium-induced keratinocyte differentiation. J Am Acad Dermatol. 1997;37:42–52.
- Halder RM, Taliaferro SJ. Vitiligo. In Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's dermatology in general medicine. 7th edition. New York: The Mcgraw-Hill Companies, 2008. p 616–622.
- Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UVB radiation vs topical psoralen plus UV-A. Arch Dermatol. 1997;133:1525–1528.
- Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and q-switched ruby laser. J Am Acad Dermatol. 2000;42:760–769.
- Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol. 2001;44:999–1003.
- Yones SS, Palmer RA, Garibaldonos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs narrowband-UV-B therapy. Arch Dermatol. 2007;143:643–646.
- Kanwar AJ, Dogra S, Parsad D, Kumar B. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Int J Dermatol. 2005;44:57–60.
- Akman A, Yılmaz E. Narrow-band ultraviolet B for the treatment of vitiligo. Turkderm. 2006;40:130–132.
- Kullavanijaya P, Lim HW. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo. Photodermatol Photoimmunol Photomed. 2004;20:248–251.
- Dogra S, Parsad D. Combination of narrowband UVB and topical calcipotriene in vitiligo. Arch Dermatol. 2003;139:393.
- Goktas EO, Aydin F, Senturk N, Canturk MT, Turanli AY. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. JEADV. 2006;20:553–557.
- Ada S, Sahin S, Boztepe G, Karaduman A, Kölemen F. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed. 2005;21:79–83.
- Hartmann A, Lurz C, Hamm H, Bröcker EB, Hofmann UB. Narrow-band UVB 311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol. 2005;44:736–742.
- Nordal E, Guleng G, Rönnevig J. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study. J Eur Acad Dermatol Venereol. 2011;25:1440–1443.